Maze Therapeutics (MAZE) Interest Expenses (2026)

Maze Therapeutics has reported Interest Expenses for 3 years, with the latest figure at -$3.7 million in Q1 2026.

• Quarterly Interest Expenses changed N/A year-over-year to -$3.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.7 million (changed N/A YoY) and the FY2025 annual result came in at $163.5 million, up 85.51% from the prior year.
• Interest Expenses fell to -$3.7 million in Q1 2026 per MAZE's latest filing, from $112.0 million in the prior quarter.
• Over five years, Interest Expenses peaked at $112.0 million in Q4 2025 and troughed at -$3.7 million in Q1 2026.
• A 3-year average of $36.3 million and a median of $494000.0 in 2024 frame the typical range for Interest Expenses.
• The widest YoY moves for Interest Expenses: up 22578.14% in 2025, down 22578.14% in 2025.
• Over 3 years, Interest Expenses stood at $494000.0 in 2024, then surged by 22578.14% to $112.0 million in 2025, then sank by 103.34% to -$3.7 million in 2026.
• According to Business Quant data, Interest Expenses over the past three periods registered -$3.7 million, $112.0 million, and $494000.0 for Q1 2026, Q4 2025, and Q4 2024 respectively.